Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11075172 | 0.82 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL3041230 | 0.81 | CYP3A4 (0.39) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL11029225 | 0.79 | CYP3A4 (0.38) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL158257 | 0.77 | GAA (0.37) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL25228829 | 0.76 | TDP1 (0.34) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8668365 | 0.76 | CYP3A4 (0.37) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL22783272 | 0.76 | TSHR (0.38) | TDP1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8668332 | 0.76 | MEN1 (0.31) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL17710673 | 0.75 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL11075175 | 0.75 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | claimed |
| WO-2023247604-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | FIRMENICH SA (CH) | 2023-12-28 | — | — | WO | claimed |
| US-11364184-B2 | Perfume compositions | GIVAUDAN SA (CH) | 2022-06-21 | — | — | US | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-4711010-A2 | PRO-PERFUME COMPOSITIONS | Firmenich SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250263631-A1 | PRO-PERFUME COMPOSITIONS | FIRMENICH SA (CH) | 2025-08-21 | — | — | US | disclosed |
| US-20250257284-A1 | ALKYL ENOL ETHER PROPERFUME | FIRMENICH SA (CH) | 2025-08-14 | — | — | US | disclosed |
| US-12325839-B2 | Pro-perfume compositions | FIRMENICH SA (CH) | 2025-06-10 | — | — | US | disclosed |
| US-12291691-B2 | Alkyl enol ether properfume | FIRMENICH SA (CH) | 2025-05-06 | — | — | US | disclosed |
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| CN-111936457-B | Enol ether pro-fragrances | 弗门尼舍有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-112752744-B | Alkylenol ether pro-fragrances | 弗门尼舍有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20100248390-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS | DUKE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| CN-101617036-A | Benefit agent delivery compositions | PROCTER & GAMBLE | 2009-12-30 | — | — | CN | disclosed |
| CN-101611129-A | Benefit agent delivery compositions | PROCTER & GAMBLE (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2079436-A1 | ALPHA, BETA, UNSATURATED NITRILES AS FRAGRANCES | Givaudan SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008037105-A1 | ALPHA, BETA, UNSATURATED NITRILES AS FRAGRANCES | GIVAUDAN SA (CH) | 2008-04-03 | — | — | WO | disclosed |
| EP-1707185-A1 | Solvent materials and methods for preparing fragrance compositions | INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) | 2006-10-04 | — | — | EP | disclosed |
| US-6410504-B1 | MIXING WITH ORGANOLEPTIC | FIRMENICH, SA (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6180814-B1 | COMPOUNDS WHICH POSSESS EXCELLENT STABILITY IN AGGRESSIVE MEDIA, ODOR VERY SIMILAR TO THAT OF CITRAL | FIRMENICH SA (CH) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257284-A1 | ALKYL ENOL ETHER PROPERFUME | CYP2E1, ACADM, ADH5 | TDP1 3006/4885MEN1 2018/4885CYP3A4 36/4885 |
| US-12291691-B2 | Alkyl enol ether properfume | CYP2E1, ACADM, ADH5 | TDP1 3006/4885MEN1 2018/4885CYP3A4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.